Reduced incidence of Type 1 diabetes and Type 2 diabetes in systemic sclerosis: A nationwide cohort study - 03/05/16
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
The purpose of this study is to investigate whether systemic sclerosis is a risk factor for diabetes.
Methods |
From Taiwan's National Health Insurance Research Database and Registry of Catastrophic Illness database, we enrolled patients with systemic sclerosis and controls. Each systemic sclerosis patient was matched to at most three controls by sex, age, month and year of first diagnosis. Standardized incidence ratio (SIR) of diabetes in systemic sclerosis patients, and 95% confidence interval (95% CI) were calculated. Cox hazard regression was used to calculate the hazard ratio (HR).
Results |
A total of 2671 patients with systemic sclerosis and 7769 controls were enrolled. Patients with systemic sclerosis had decreased type 1 diabetes (SIR: 0.18, 95% CI=0.04–0.82). In female groups, systemic sclerosis patients also had lower rates of incident type 1 diabetes (SIR: 0.21, 95% CI=0.05–0.95). Male and female patients with systemic sclerosis both had lower rates of incident type 2 diabetes (SIR: 0.46, 95% CI=0.29–0.72; SIR: 0.41, 95% CI=0.33–0.51, respectively). Systemic sclerosis patients had decreased type 1 diabetes and type 2 diabetes (HR: 0.18, 95% CI=0.04–0.74; HR: 0.42, 95% CI=0.36–0.50, respectively) after adjusting for age and sex.
Conclusions |
The results clearly showed that patients with systemic sclerosis had lower incidence of type 1 diabetes and type 2 diabetes compared to control subjects.
Le texte complet de cet article est disponible en PDF.Keywords : Systemic sclerosis, Diabetes, Retrospective cohort study, Hazard rate
Plan
Vol 83 - N° 3
P. 307-313 - mai 2016 Retour au numéro
Article précédent
- Can ARFI elastometry of the salivary glands contribute to the diagnosis of Sjögren's syndrome?
- Anne Samier-Guérin, Alain Saraux, Simon Gestin, Divi Cornec, Thierry Marhadour, Valérie Devauchelle-Pensec, Luc Bressollette, Michel Nonent, Sandrine Jousse-Joulin
- Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment
- Thomas Bardin, Gérard Chalès, Tristan Pascart, René-Marc Flipo, Hang Korng Ea, Jean-Claude Roujeau, Aurélie Delayen, Pierre Clerson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?